• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Indacaterol/glycopyrronium superior to salmeterol/fluticasone in reducing annual COPD exacerbations: The FLAME Study

byShayna BejaimalandShaidah Deghan, MSc. MD
June 10, 2016
in Chronic Disease, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. Indacaterol/glycopyrronium significantly reduced annual COPD exacerbation rates as compared to standard therapy with salmeterol/fluticasone.

2. The adverse events and deaths were similar across both groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Frequent COPD exacerbations are associated with reduced quality of life, mortality and increased hospital costs, thus regimens to reduce exacerbations are important. Guidelines suggest that those with frequent exacerbations should use inhaled long acting glucocorticoids and long acting beta-agonists (LABA). However, the alternative of a LABA and a long-acting muscarinic antagonist (LAMA) also exists. Given potential side effects from long-term use of inhaled glucocorticoids, the efficacy of the LABA/LAMA combination as compared to standard of care is unclear. This randomized controlled trial aimed to determine if the LABA indacaterol and LAMA glycopyrronium were at least as effective as the LABA salmeterol and the inhaled glucocorticoid fluticasone.

The LABA/LAMA combination of indacaterol/glycopyrronium was not only noninferior but also superior to standard of care. The LABA/LAMA group also had longer time to first exacerbation in all severities of COPD exacerbation. The incidence of adverse events and deaths were similar in both groups. However, the incidence of pneumonia (a presumed side effect from long-term inhaled glucocorticoids) was statistically higher in the salmeterol/fluticasone group. Limitations of this study include its per-protocol analysis for the primary outcome and pharmaceutical company involvement in trial design and reporting.

Click to read the study, published today in NEJM

RELATED REPORTS

Pulmonary arterial pruning and longitudinal change in percent emphysema and lung function

#VisualAbstract: Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

Relevant Reading: Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease

In-Depth [randomized controlled trial]: The FLAME trial was a multi-centre, randomized, double-blind, double-dummy, parallel-group, non-inferiority trial. Patients were 40 or older, with grade 2 or higher COPD on the MRC scale, had a post-bronchodilator FEV-1 of at least 25% to <60% of predicted value. Patients also must have had a COPD exacerbation in the year previous to enrollment. After a 1-week long run-in period with tiotropium (18ÎĽg), patients were randomly assigned in a 1:1 ratio to receive indacaterol (110ÎĽg) plus glycopyrronium (50ÎĽg) once daily or salmeterol (50ÎĽg) plus fluticasone (500ÎĽg) twice daily for 52 weeks. They were followed for an additional 30 days after regimen discontinuation. All patients had access to open-label salbutamol (100ÎĽg) as a rescue medication. The primary objective of this trial was to show that the LABA/LAMA combination would be non-inferior to LABA/Inhaled glucocorticoids in reducing the rate of COPD exacerbations. The safety of both treatment regimens was analyzed.

A total of 1680 patients were assigned to LABA/LAMA and 1682 to LABA/inhaled glucocorticoid. Indacaterol/glycopyrronium was not only noninferior but also superior to salmeterol/fluticasone in reducing annual COPD exacerbation rate. There was an 11% reduction in the LABA/LAMA group as compared to LABA/inhaled glucocorticoid (3.59 vs. 4.03; RR=0.89, 95% [CI], 0.83-0.96, p=0.003). There was a longer time to first COPD exacerbation in all severities in the LABA/LAMA group (71 days vs. 51 days; HR=0.84, 95% [CI]: 0.78-0.91; P<0.001). There was no difference in adverse events or mortality across the two treatment regimens. The only difference was an increased incidence of pneumonia in the salmeterol/fluticasone group (3.2% vs. 4.8%; p=0.02)

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: copd
Previous Post

2 Minute Medicine Rewind June 6, 2016

Next Post

Artificial pancreas may decrease hypoglycemic episodes in type I diabetic children

RelatedReports

2 Minute Medicine Rewind May 20, 2019
Pulmonology

Pulmonary arterial pruning and longitudinal change in percent emphysema and lung function

February 24, 2021
#VisualAbstract: Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for maintenance of HIV-1 viral suppression
StudyGraphics

#VisualAbstract: Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

January 6, 2021
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Infectious Disease

Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

December 27, 2020
Quick Take: The burden of health conditions for middle-aged and older adults in the United States: disability-adjusted life years
Cardiology

Quick Take: The burden of health conditions for middle-aged and older adults in the United States: disability-adjusted life years

April 22, 2019
Next Post
Food environment associated with gestational diabetes

Artificial pancreas may decrease hypoglycemic episodes in type I diabetic children

Needlestick injuries most common in first six months of residency

Robotic surgery faster with similar outcomes for endometrial cancer

E-cigarette use may increase risk of smoking cigarettes in teens

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.